title: Primary neuroendocrine carcinoma of the breast, which chemotherapy?
authors.forename: L K
authors.initials: LK
authors.lastname: El Hassani
authors.forename: Y
authors.initials: Y
authors.lastname: Bensouda
authors.forename: H
authors.initials: H
authors.lastname: M'Rabti
authors.forename: S
authors.initials: S
authors.lastname: Boutayeb
authors.forename: M
authors.initials: M
authors.lastname: Kamouni
authors.forename: L
authors.initials: L
authors.lastname: Gamra
authors.forename: H
authors.initials: H
authors.lastname: Errihani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D017211:Treatment Failure
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil